Back to Agenda
FDA Town Hall
Session Chair(s)
Amy Bertha
Executive Director, Regulatory Policy and Science
Bayer, United States
The FDA Town Hall provides a unique opportunity to hear directly from FDA leadership about key priorities. This year’s session will explore the evolving intersection of artificial intelligence (AI), real-world data (RWD), and real-world evidence (RWE), and how these elements are shaping drug and biologics development, regulatory expectations, and patient engagement.
Learning Objective : Discuss FDA Center priorities.
Speaker(s)
Panelist
Marie Bradley, PhD, MPH, MPharm
FDA, United States
Senior Advisor, Real-World Evidence , Office of Medical Policy, CDER
Panelist
Tamei Elliott, MS
DIA, United States
Director, Global Scientific Content
Panelist
Hussein Ezzeldin, PhD
FDA, United States
Associate Director for Advanced Technologies, OBPV, CBER
Panelist
Tala Fakhouri, PhD, MPH
FDA, United States
Associate Director for Data Science and Artificial Intelligence, CDER
Panelist
Gabriel Innes, DVM, PhD
FDA, United States
Assistant Director for Data Science and Artificial Intelligence, CDER
Panelist
Shantanu Nundy, MD
Johns Hopkins Carey School of Business, United States
Adjunct professor, courtesy appointment
Panelist
Jeremy Walsh
FDA, United States
Chief AI Officer, OC
Have an account?